Targeting Toll-like receptors: emerging therapeutics?
Elizabeth J. Hennessy(Translational Therapeutics (United States)), Luke O'neill(Trinity College Dublin)
Cited by 883
Related Papers
Metabolic reprogramming in macrophages and dendritic cells in innate immunity
|Cell Research|2015|1.8k
Trained immunity, tolerance, priming and differentiation: distinct immunological processes
|Nature Immunology|2020|591
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
|Cell Metabolism|2020|571
Targeting immunometabolism as an anti-inflammatory strategy
|Cell Research|2020|552
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
|Pharmacological Reviews|2009|422